Clinical Trials Directory

Trials / Unknown

UnknownNCT02382900

Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City

Evaluation of a Two-dose Schedule of Quadrivalent Human Papilloma Virus (Types 6, 11, 16, 18) Recombinant Vaccine in 11-year-old Boys in Mexico City (Gardasil® Merck and Co.).

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
500 (estimated)
Sponsor
Universidad Nacional Autonoma de Mexico · Academic / Other
Sex
All
Age
10 Years – 11 Years
Healthy volunteers
Accepted

Summary

In the genital tract human papilloma virus (HPV), especially types 6 and 11 cause genital warts, the commonest viral sexually transmitted disease. The HPV 16 and 18 are the most common oncogenic "high-risk" genotypes and cause approximately 70% of all cervical cancers despite the fact that are associated with other anogenital cancers, anus, vagina, vulva and penis, and cancers of the head and neck. Current estimates are that 5.2% of all cancers are HPV associated. A large number of studies, including both adult and young females, have demonstrated that HPV vaccines are highly immunogenic and induce a long lasting protection against infection. Immunogenic vaccination results in young men and boys are equally satisfactory with the quadrivalent HPV (types 6, 11, 16, 18) vaccine recommended for men. The recommended vaccination scheme includes three shots giving the second at two months and the third at six months after the initial shot. Recently, it has been shown that the use of a two shot scheme (0 and 6 months) is equally effective among girls. The purpose of this study is to determine that the immunogenicity is non-inferior in boys using a two shot scheme compared with young women and girls.

Conditions

Interventions

TypeNameDescription
BIOLOGICALquadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccinedose scheme (0 and 6 month)

Timeline

Start date
2015-02-01
Primary completion
2015-10-01
Completion
2015-12-01
First posted
2015-03-09
Last updated
2015-03-09

Locations

1 site across 1 country: Mexico

Source: ClinicalTrials.gov record NCT02382900. Inclusion in this directory is not an endorsement.